Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Land & Improvements (2021 - 2025)

Abvc Biopharma (ABVC) has disclosed Land & Improvements for 4 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Land & Improvements rose 1145.37% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Dec 2025, up 1145.37%, and an annual FY2025 reading of $4.2 million, up 1145.37% over the prior year.
  • Land & Improvements was $4.2 million for Q4 2025 at Abvc Biopharma, roughly flat from $4.2 million in the prior quarter.
  • Across five years, Land & Improvements topped out at $4.2 million in Q3 2025 and bottomed at $334520.0 in Q1 2025.
  • Average Land & Improvements over 4 years is $1.5 million, with a median of $378975.0 recorded in 2025.
  • The sharpest move saw Land & Improvements fell 9.72% in 2022, then soared 1145.37% in 2025.
  • Year by year, Land & Improvements stood at $400091.0 in 2021, then decreased by 9.72% to $361193.0 in 2022, then fell by 6.15% to $338966.0 in 2024, then skyrocketed by 1145.37% to $4.2 million in 2025.
  • Business Quant data shows Land & Improvements for ABVC at $4.2 million in Q4 2025, $4.2 million in Q3 2025, and $378975.0 in Q2 2025.